Pantoprazole Krka

Pantoprazole, the active ingredient in Pantoprazole Krka, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders in adults.

GNH USA supplies Pantoprazole Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole is a proton pump inhibitor that acts on the gastric parietal cell to lower acid secretion, addressing several acid‑related conditions. - Gastro‑oesophageal reflux disease (GERD): relieves heartburn and promotes healing of the esophageal lining. - Erosive oesophagitis: facilitates mucosal repair and reduces further erosion. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors. - NSAID‑induced ulcer prophylaxis: helps prevent ulcer formation in patients requiring long‑term non‑steroidal anti‑inflammatory drug therapy.

Pantoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools, usually transient. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea. - Low magnesium levels: muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: abnormal blood test results. - Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

Before initiating therapy, consider the following safety measures. - Assess renal function: adjust use in severe impairment. - Evaluate hepatic status: monitor in patients with liver disease. - Review concomitant medications: avoid unnecessary drug combinations. - Pregnancy and lactation: use only if clearly needed after risk‑benefit analysis. - Long‑term therapy: periodically reassess need to minimize fracture risk. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Pantoprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Ketoconazole: reduced absorption; avoid concurrent use. - Atazanavir: markedly decreased exposure; contraindicated. - Warfarin: potential increase in anticoagulant effect; monitor INR closely.

Moderate Interactions (Monitor Closely): - Digoxin: may increase serum levels; check concentrations. - Methotrexate (high dose): possible accumulation; monitor renal function. - Iron supplements: decreased absorption; separate dosing by at least 2 hours.